HomeLab TestsAlpha Fetoprotein (AFP) Tumor Marker Test
Back to Lab Tests
Alpha Fetoprotein (AFP) Tumor Marker Test
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Lab Tests

Alpha Fetoprotein (AFP) Tumor Marker Test

The AFP tumor marker test measures protein levels in the blood to help monitor certain cancers and liver conditions in non-pregnant individuals.

Overview

Alpha-fetoprotein (AFP) is a protein produced by the liver during fetal development. In healthy children and adults who are not pregnant, AFP levels are very low. When measured in non-pregnant individuals, AFP acts as a tumor marker—a substance produced by cancer cells or by normal cells in response to cancer.

Clinical Uses

While an AFP tumor marker test cannot diagnose cancer on its own, it is used in conjunction with imaging tests (such as ultrasound, CT, or MRI) and other markers like PIVKA-II or AFP-L3% for the following purposes:

  • Monitoring treatment: Tracking whether AFP levels decrease as tumors shrink during cancer therapy.
  • Prognosis: Helping providers understand the stage and potential growth rate of a cancer.
  • Detecting recurrence: Checking if cancer has returned after treatment.
  • Monitoring chronic liver disease: Used alongside ultrasound every six months to detect early signs of liver cancer in patients with cirrhosis or chronic hepatitis B or C.

Conditions Associated with High AFP

High levels of AFP may be associated with:

  • Cancer: Specifically liver cancer (hepatocellular carcinoma), ovarian cancer, or testicular cancer.
  • Non-cancerous liver conditions: Such as cirrhosis or chronic hepatitis B or C.

Understanding Results

Results must be interpreted within the context of your medical history:

  • High levels: May indicate cancer or liver injury. However, because not all tumors produce AFP, a normal result does not definitively rule out cancer.
  • During treatment: Decreasing levels generally suggest treatment is working, while increasing levels may indicate the treatment is ineffective or the cancer is growing.
  • Post-treatment: Rising levels may signal that cancer has returned.

If you have chronic liver disease, a sudden spike in AFP levels may prompt your provider to order further diagnostic testing to screen for liver cancer.

Frequently Asked Questions

No. AFP lacks sufficient sensitivity and specificity to serve as a stand‑alone screening tool in the general population. It is most useful in patients with cirrhosis or chronic hepatitis B/C who are already undergoing regular ultrasound surveillance; even then, a normal AFP does not exclude early HCC.
Guidelines recommend measuring AFP together with a liver ultrasound every six months for patients with cirrhosis or chronic hepatitis B at high risk for HCC. Your hepatologist may adjust the interval based on individual risk factors, prior AFP trends, or new symptoms.
normal AFP does not rule out malignancy because many HCCs and germ‑cell tumors do not secrete AFP. Imaging characteristics (arterial enhancement, washout on portal venous phase) and, when needed, biopsy are required to determine the nature of the nodule.
In most laboratories, an AFP level above 20 ng/mL is flagged as elevated for non‑pregnant adults. Levels between 20‑200 ng/mL may occur with chronic liver disease or early hepatocellular carcinoma (HCC), while values >200 ng/mL strongly suggest HCC or germ‑cell tumors. Interpretation always requires correlation with imaging, clinical history, and other markers (e.g., AFP‑L3, PIVKA‑II).
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss